Implementation and Impact of National Centralized Drug Procurement Policy in China: Evidence from the National Drug Procurement Database
Jiancheng Lu,Ying Yang,Xiaotong Wen,Jing Wang,Yuan Shen,Lining Mao,Dan Cui,Zongfu Mao,Jinghua Li
DOI: https://doi.org/10.21203/rs.3.rs-805352/v1
2021-08-19
Abstract:Abstract Background Chinese government implemented the first round of National Centralized Drug Procurement pilot in 4 municipalities and 7 sub-provincial cities in 2019, so called "4 + 7" policy. This study evaluated the implementation and impact of “4 + 7” policy. Methods This study used drug purchase data from China Drug Supply Information Platform (CDSIP) database. “4 + 7” policy-related drugs were selected as study samples, including 25 drugs in the “4 + 7” List and 92 alternative drugs that have an alternative relationship with “4 + 7” List drugs in clinical use. “4 + 7” List drugs were divided into bid-winning and non-winning products. We applied Defined Daily Doses (DDDs), DDDs per 1000 inhabitants per day (DID), purchase expenditures, and Defined Daily Drug cost (DDDc) as outcome variables. Interrupted time-series was adopted to quantity policy effect. Results As of December 2019, the completion rate of overall bid-winning drugs in 9 pilot cities reached 154.40%, and the completion rate of 25 bid-winning drugs ranged between 74.77% and 477.75%. After policy intervention, the DID of bid-winning drugs, “4 + 7” List drugs, alterative drugs, as well as the overall policy-related drugs increased by 545.18%, 14.03%, 12.21%, and 13.04% in pilot cities. Bid-winning drugs significantly increased 132.84 million DDDs ( p < 0.001) in volume and 48.95 million CNY ( p < 0.05) in expenditures, and dropped 6.35 CNY ( p < 0.001) in DDDc. The volume proportion of bid-winning products increased from 12.67–71.66%. The DDDc of non-winning drugs increased 0.94 CNY ( p < 0.001). Overall, the DDDc of policy-related drugs dropped 1.38 CNY ( p < 0.001), and the expenditures decreased 634.68 million CNY ( p < 0.001). Conclusion An overall satisfying implementation progress of “4 + 7” policy was observed in pilot cities. The policy alleviated the medication burdens of patients, which is supported by the significant reduction in DDDc and costs of policy-related drugs. The accessibility and consumption of policy-related drugs improved. However, monitoring regarding the clinical use of policy-related drugs will still be necessary in the future.